Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixmyelocel-T - Vericel

Next Previous
X
Search
Drug Profile

Ixmyelocel-T - Vericel

Alternative Names: Bone Repair Cells - Vericel Corporation; BRC therapy - Vericel Corporation; Cardiac Repair Cells - Vericel Corporation; CRC therapy - Vericel Corporation; Tissue Repair Cells - Vericel Corporation; Tissue repair stem cell therapy - Vericel Corporation; TRC therapy - Vericel Corporation; Vascular Repair Cells - Vericel Corporation; VRC therapy - Vericel Corporation

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aastrom Biosciences
  • Developer Aastrom Biosciences; University of Michigan; Vericel Corporation
  • Class Haematopoietic stem cells therapies; Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteonecrosis; Dilated cardiomyopathy
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alveolar bone loss; Dilated cardiomyopathy
  • Suspended Peripheral ischaemia
  • No development reported Atherosclerosis; Neurodegenerative disorders
  • Discontinued Non-union fracture; Osteoarthritis; Osteonecrosis; Osteoporosis; Vertebral fracture

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in USA
  • 10 May 2017 Ixmyelocel-T licensed to Innovative Cellular Therapeutics in China, South Korea, Singapore, and other countries in South East Asia
  • 10 May 2017 Ixmyelocel-T receives Regenerative Medicine Advanced Therapy (RMAT) designation from US FDA for Dilated cardiomyopathy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top